7 TWENTYFOURSEVENBIOPHARMA Issue 1 / March 2025 it as a center of excellence in the Axplora network for contract manufacturing of APIs and drug substances for FDA-approved biologics. This investment demonstrates Axplora’s dedication to partnering with leading pharmaceutical companies, fostering innovation, supporting local economic growth, and delivering life-changing therapies to patients worldwide. By upgrading Mourenx’s infrastructure and capabilities, Axplora will solidify its position in peptide purification in a biologics environment and support the development of next-generation therapies, including GLP-1 drugs that target diabetes and obesity— some of society’s most urgent health challenges. “GLP-1 therapies represent a paradigm shift in medicine, offering targeted therapies for complex diseases with unprecedented efficacy and tolerability,” said Arul Ramadurai, Chief Commercial Officer. “This initiative, built on strong customer partnerships, reinforces Axplora’s role as a trusted partner in manufacturing lifechanging, breakthrough medicines.” “This project is testament to our pioneering expertise in industrial chromatography, and working closely with our client, we target having the facility BLA-ready in 15 months. To achieve this our internal teams are working closely with partners in a strong crossfunctional project team, wellsupported by the local authorities. We are looking forward to a bright future at Mourenx,” stated Dr. Pere Patón-Morales, Chief Operating Officer. Construction and infrastructure development will begin immediately, with first supplies of GLP-1 therapies expected in 2026. This investment ensures the Mourenx site will remain a key contributor to Axplora’s API network well into the 2030s and beyond. Cerbios-Pharma is proud to announce the opening of a new expansion area at the Lugano site for clinical and commercial manufacturing of Highly Potent Active Pharmaceutical Ingredients (HPAPIs), including cytotoxic linker payloads for antibodydrug conjugates (ADCs). The inauguration was conducted in the presence of Christian Suà, CEO of Cerbios-Pharma, and the members of Cerbios team whose expertise and commitment made this expansion possible. The manufacturing unit is equipped with isolator containment technology for highly potent molecules down to an OEL <10 ng/m3. This advanced facility ensures maximum flexibility to accommodate a wide range of molecule types. With the investment, Cerbios offers expanded capacity for state-of-the-art purification technologies such as high and low pressure chromatography, nanofiltration and freezedrying The new area is located within the latest constructed facility which was approved by Swissmedic in 2023, providing an immediate additional capacity to serve the increasing market demand for this product category. This milestone reinforces Cerbios-Pharma’s strategic investment in high-potency manufacturing and strengthens its position as a leading CMO in the commercial supply of HPAPIs and ADCs. Cerbios-Pharma S.A. boosts production capabilities for HPAPIs and ADCs NEWS
RkJQdWJsaXNoZXIy MjY2OTA4MA==